Why the study?
Hypertension is a modifiable precursor to heart failure, but randomized clinical trials are limited and underenroll female, minority, elderly, or treatment-resistant patients.
Does intensive blood pressure control reduce incident heart failure in high-risk populations?
Does intensive blood pressure control reduce incident heart failure in high-risk populations?
This review emphasizes the critical need for future hypertension trials to enroll diverse, high-risk populations to accurately determine optimal blood pressure targets for heart failure prevention.
Answers are grounded in this paper and cite their sources.
Intensive BP control findings cannot yet guide HF prevention in underrepresented high-risk groups; leaves open optimal targets pending inclusive trials.
PURPOSE OF REVIEW: Hypertension is a common, modifiable precursor to heart failure. Lifetime risk for development varies across age, sex, race and ability to achieve adequate blood pressure control. RECENT FINDINGS: Although meta-analyses seemingly support intensive blood pressure control to reduce incident heart failure, randomized clinical trials are limited and do not enroll a large number of female, minority, elderly or treatment-resistant patients. Heterogeneity further adds to complexity; however, enhanced cognizance of these disparities can aid clinicians in creating patient-centered care plans. SUMMARY: High-risk populations constitute an overwhelming percentage of the comorbid disease burden. Future clinical trials must reflect this diverse population to truly determine appropriate blood pressure targets and pharmacotherapy to reduce cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Katherine E. Di Palo (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: